EUCTR2014-003877-40-DE进行中（未招募）1 期
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have completed a patisiran study
- •2. Adequate liver function and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 114
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 114
排除标准
- •1. Pregnant or nursing
- •2. Have uncontrolled clinically significant cardiac arrhythmia or unstable angina
研究者
相似试验
进行中（未招募）
1 期
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301EUCTR2012-003176-39-IEBiogen Idec Research Limited1,600
已完成
不适用
ALN-TTR02-006Hereditary transthyretin-mediated amyloidosis(hATTR amyloidosis)JPRN-jRCT2080224174Alnylam Pharmaceuticals, Inc. / Medpace Japan KK211
进行中（未招募）
1 期
Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)Transthyretin mediated amyloidosis (ATTR)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003877-40-CYAlnylam Pharmaceuticals, Inc.228
进行中（未招募）
1 期
Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)Transthyretin mediated amyloidosis (ATTR)MedDRA version: 20.0Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2014-003877-40-ITALNYLAM PHARMACEUTICALS, INC.228
进行中（未招募）
1 期
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301Relapsing-remitting Multiple SclerosisMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003176-39-CZBiogen Idec Research Limited1,600